IgPro20 + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-COVID Postural Orthostatic Tachycardia Syndrome
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome
Trial Timeline
Aug 28, 2024 → Jul 11, 2025
NCT ID
NCT06524739About IgPro20 + Placebo
IgPro20 + Placebo is a phase 3 stage product being developed by CSL for Post-COVID Postural Orthostatic Tachycardia Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT06524739. Target conditions include Post-COVID Postural Orthostatic Tachycardia Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06524739 | Phase 3 | Terminated |
Competing Products
6 competing products in Post-COVID Postural Orthostatic Tachycardia Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abrocitinib + Placebo | Pfizer | Phase 2 | 51 |
| Nirmatrelvir/ritonavir + Placebo/ritonavir | Pfizer | Phase 2 | 51 |
| Efgartigimod | Argenx | Phase 2 | 49 |
| Vericiguat Oral Tablet | Bayer | Phase 2 | 49 |
| Meplazumab for injection | Pacific Biosciences | Phase 3 | 69 |
| Vortioxetine + Placebo | Brain Biotech | Phase 2 | 44 |